Myovant Sciences company information, Employees & Contact Information

Sumitovant Biopharma Completes Acquisition of Myovant Sciences PR Newswire

Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022 Yahoo Finance

Myovant Sciences Announces Corporate Updates and Financial Results for Second Fiscal Quarter 2022 GlobeNewswire

NCCN awards funding to 4 advanced prostate cancer research projects Urology Times

Myovant agrees to sell after buyer ups price BioPharma Dive

Weeks after Rejecting First Offer, Myovant Agrees to Acquisition by Sumitovant BioSpace

Relugolix demonstrates positive phase 3 data as combination therapy for endometriosis pain Contemporary OB/GYN

Orgovyx Approved for Advanced Prostate Cancer Medical Professionals Reference

Myovant endometriosis survey shows women consider quitting work, school due to symptoms Fierce Pharma

Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement PR Newswire

Myovant Sciences Appoints Industry Veteran David Marek as Chief Executive Officer Yahoo Finance

Myovant Sciences and Accord Healthcare, Ltd. Enter into GlobeNewswire

Myovant rejects $2.4B buyout offer from Japanese majority owner BioPharma Dive

FDA accepts Myfembree sNDA for bleeding associated with uterine fibroids Contemporary OB/GYN

Myovant Sciences and Pfizer Announce Collaboration to GlobeNewswire

Sumitovant Biopharma Has a Strong Fourth Quarter with Significant Clinical Development and Corporate Achievements Across its Portfolio of Companies PR Newswire

FDA approves Myfembree for endometriosis pain Contemporary OB/GYN

UPDATE - Sumitovant Biopharma Announces Myovant Sciences GlobeNewswire

Myovant Sciences Ltd. Announces Pricing of Initial Public Offering PR Newswire

Myovant Sciences Announces Appointment of Board of Directors PR Newswire

Myovant Sciences and Flo Health Partner to Develop Digital Tool to Screen Women for Heavy Menstrual Bleeding PR Newswire

Myovant scores FDA nod for Orgovyx, a first-in-class pill for advanced prostate cancer Fierce Pharma

Sumitomo's improved buyout offer sways Myovant FirstWord Pharma

Sumitomo nets Myovant in $2.9B buyout, adding IVF asset to pipeline Fierce Biotech

After delay, Myovant and Pfizer's Myfembree nabs FDA nod for endometriosis Fierce Pharma

Sumitomo Offers to Buy All of Myovant in Deal Worth $2.5 Billion Bloomberg

Myovant and Pfizer's uterine fibroids med scores FDA nod, setting up showdown with AbbVie Fierce Pharma

Sumitovant Biopharma’s Portfolio of Innovative Companies GlobeNewswire

Myovant, Pfizer's expansion bid for Myfembree hits a snag at the FDA Fierce Pharma

Myovant leans on new partner Pfizer as it dives into first launch for cancer drug Orgovyx Fierce Pharma

Myovant and Pfizer Ink $4.2 Billion Deal for Orgovyx in Oncology and Women’s Health BioSpace

Myovant's endometriosis med hits the mark in phase 3, setting up AbbVie face-off Fierce Biotech

Sumitovant Biopharma Acquires Women’s Health Pharma Company Myovant Sciences for $1.7B Femtech Insider

As Pfizer, Myovant's bid to expand Myfembree use draws near, Myovant teases speedy launch plans Fierce Pharma

Myovant bumps IPO to $218M with Pfizer, BB Biotech aid Fierce Biotech

Myovant, Gedeon Richter’s uterine fibroids med Ryeqo bags EU approval PharmaTimes

Asian trial backs Takeda and Myovant’s relugolix in uterine fibroids Fierce Biotech

Myovant Sciences Ltd. (MYOV) Q1 2021 Earnings Call Transcript The Motley Fool

Takeda and Roivant launch Myovant Sciences Ltd European Pharmaceutical Review

$3B package deal to push Peninsula company into arms of Japanese drugmaker The Business Journals

Myovant Sciences and Accord Healthcare enter into exclusive licence agreement to commercialise Orgovyx for prostate cancer in Europe Express Pharma